These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
317 related articles for article (PubMed ID: 23307860)
1. New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential. Banerjee S; Kaye SB Clin Cancer Res; 2013 Mar; 19(5):961-8. PubMed ID: 23307860 [TBL] [Abstract][Full Text] [Related]
2. Targeted molecular therapies for ovarian cancer: an update and future perspectives (Review). Shigetomi H; Higashiura Y; Kajihara H; Kobayashi H Oncol Rep; 2012 Aug; 28(2):395-408. PubMed ID: 22641286 [TBL] [Abstract][Full Text] [Related]
3. New perspectives in ovarian cancer treatment. Schmid BC; Oehler MK Maturitas; 2014 Feb; 77(2):128-36. PubMed ID: 24380827 [TBL] [Abstract][Full Text] [Related]
5. Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. McCubrey JA; Steelman LS; Kempf CR; Chappell WH; Abrams SL; Stivala F; Malaponte G; Nicoletti F; Libra M; Bäsecke J; Maksimovic-Ivanic D; Mijatovic S; Montalto G; Cervello M; Cocco L; Martelli AM J Cell Physiol; 2011 Nov; 226(11):2762-81. PubMed ID: 21302297 [TBL] [Abstract][Full Text] [Related]
6. Successes and limitations of targeted cancer therapy in ovarian cancer. Damia G; Sessa C Prog Tumor Res; 2014; 41():89-97. PubMed ID: 24727989 [TBL] [Abstract][Full Text] [Related]
7. Targeted agents and combinations in ovarian cancer: where are we now? McLachlan J; Lima JP; Dumas L; Banerjee S Expert Rev Anticancer Ther; 2016; 16(4):441-54. PubMed ID: 26942837 [TBL] [Abstract][Full Text] [Related]
8. Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer. Saini KS; Loi S; de Azambuja E; Metzger-Filho O; Saini ML; Ignatiadis M; Dancey JE; Piccart-Gebhart MJ Cancer Treat Rev; 2013 Dec; 39(8):935-46. PubMed ID: 23643661 [TBL] [Abstract][Full Text] [Related]